White House lays out new COVID plan, will stockpile tests and pills
The 96-page plan says the nation no longer needs to "let COVID-19 dictate how we live."
Alexander Tin is a digital reporter for CBS News based in the Washington, D.C. bureau. He covers the Biden administration's public health agencies, including the federal response to infectious disease outbreaks like COVID-19. Previously, he was a campaign reporter for CBS News based out of Las Vegas, where he was raised. He covered presidential, Senate and House candidates for the 2020 election cycle in Arizona, California, Nevada and New Mexico. He has also worked in Washington for "Face the Nation" and in New York for the "CBS Evening News." Tin graduated from Columbia University in 2017 with a bachelor's degree in political science.
The 96-page plan says the nation no longer needs to "let COVID-19 dictate how we live."
New data published from the CDC found booster shots appeared to restore protection.
New guidance issued by the agency adds an emphasis on hospitalization data to decide COVID-19 measures.
Study's authors say their new data underscore the urgency for governments to address the pandemic's toll on orphaned children.
The White House's top COVID-19 testing official said supplies had limited their ability to ship some orders quickly.
Novavax's shots are based on a kind of "protein subunit" technology that has been used for decades in other routine vaccinations.
The CDC has modified its isolation and quarantine guidance several times since its major update last month.
Scarce supplies and the record surge in Omicron cases can make it tricky to secure the "game-changer" COVID-19 pill from Pfizer.
Researchers from Boston University analyzed data from more than 2,000 couples trying to conceive.
The highly-protective masks will be distributed through pharmacies and health centers nationwide.
The U.S. Postal Service is already collecting orders for free test deliveries – a day ahead of schedule.
Some distinctive COVID-19 symptoms, like loss of taste and smell, now appear to be less common.
Many factors can affect how likely a COVID-19 test is to correctly spot an infection.
The move follows the FDA's authorization earlier this week and an hours-long meeting of the CDC's outside advisers.
Some public health experts had criticized the agency for not requiring testing at the end of a shortened isolation.